Considering the compensatory relationship between RAS/RAF/ERK and PI3K/AKT/mTOR pathways, KRAS mutant cancer cell lines have shown a synergistic effect of PI3K and MEK inhibitors. This evidence concerns the gene KRAS and cancer.